Plantacor

Executive Summary

Plantacor is a preclinical biopharmaceutical company developing novel natural product-derived therapeutics for cancer, with an initial focus on aggressive basal-like breast cancer. The company leverages institutional research to advance compounds through preclinical evaluation and IND filing, aiming to bridge the gap between discovery and clinical development. Plantacor's lead candidate is a novel analog of a known tumor growth inhibitor, formulated to improve efficacy and safety. Founded in 2019 and headquartered in San Diego, the company is privately held and has not yet disclosed funding or valuation. As a preclinical-stage entity, Plantacor faces significant technical and regulatory risks, but its focus on an underserved cancer subtype and its strategy of optimizing natural products provide a differentiated approach. The company's progress hinges on successful preclinical data generation and IND clearance.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Candidate40% success
• Q3 2026Preclinical Efficacy Data Presentation60% success
• Q2 2027Strategic Partnership or Licensing Deal30% success